Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer’s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further eluc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Acta Neuropathol Commun
Autori principali: Wojtas, Aleksandra M., Carlomagno, Yari, Sens, Jonathon P., Kang, Silvia S., Jensen, Tanner D., Kurti, Aishe, Baker, Kelsey E., Berry, Taylor J., Phillips, Virginia R., Castanedes, Monica Casey, Awan, Ayesha, DeTure, Michael, De Castro, Cristhoper H. Fernandez, Librero, Ariston L., Yue, Mei, Daughrity, Lillian, Jansen-West, Karen R., Cook, Casey N., Dickson, Dennis W., Petrucelli, Leonard, Fryer, John D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7708249/
https://ncbi.nlm.nih.gov/pubmed/33261653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40478-020-01079-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi